Company intelligence / Profile preview

Rondo Therapeutics

Hayward, California, United Statesrondotx.com ↗

Ownership: Private
Development stage: Other

Overview

Rondo Therapeutics develops next-generation T cell-engaging bispecific antibodies designed to treat solid tumors by boosting anti-tumor immunity while minimizing toxicity. Their lead program, RNDO‑564, a CD28 x Nectin‑4 bispecific antibody for bladder cancer, has shown robust preclinical efficacy and safety. The company’s proprietary immune engager platform enables the development of tailored therapeutics with broad therapeutic windows. No clinical results are available yet; the pipeline remains in preclinical/IND-enabling stages as of early/mid‑2025.

Therapeutic areas: Oncology
Modalities: Bispecific antibodies (immune-engaging bispecifics)T cell engagers
Industry: Biotech

Drug pipeline

4 assets

RNDO-564

3 more assets in the full pipeline.

Request access →

Partnerships

Eli Lilly & Company – collaboration and license agreement to develop novel CD28 co-stimulatory bispecific antibodies for solid tumors. Lilly holds exclusive worldwide rights to a defined target under this partnership.

Beyond the preview

Go deeper on Rondo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rondo Therapeutics.

Explore the full profile